EUCTR2009-014730-22-IT进行中（未招募）不适用
SO03-01 - EVALUATION OF THE EFFECT OF N-3 SUPPLEMENTATION ON FUNCTIONAL IMPROVEMENT IN POSTSTROKE PATIENTS - SO3-01
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Principal inclusion criteria are: Patients of all ages; Patients of both sexes Patients malnourished and well-nourished Patients with previous ischemic stroke
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Principal exclusion criteria are: presence of other neurological diseases malignancies or progressive and degenerative diseases; severe liver disease; severe renal insufficiency. patients with score > 20 at mini mental test examination (for the exclusion of dementia) patients treated with antidepressants for less than a week
研究者
相似试验
已完成
不适用
Myopia control with progressive spectacle lenses trialJuvenile onset myopiaEye - Diseases / disorders of the eyeACTRN12611000582954Carl Zeiss Vision165
已完成
不适用
A study to analysis the usefulness of personalized 3D thyroid modelEndocrine, nutritional and metabolic diseaseKCT0005069ational Cancer Center60
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-FRovo Nordisk A/S372
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-FIovo Nordisk A/S372
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 20.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-DKovo Nordisk A/S288